Pivotal role of mTOR signaling in hepatocellular carcinoma.

PubWeight™: 4.03‹?› | Rank: Top 1%

🔗 View Article (PMC 2678688)

Published in Gastroenterology on August 20, 2008


Augusto Villanueva1, Derek Y Chiang, Pippa Newell, Judit Peix, Swan Thung, Clara Alsinet, Victoria Tovar, Sasan Roayaie, Beatriz Minguez, Manel Sole, Carlo Battiston, Stijn Van Laarhoven, Maria I Fiel, Analisa Di Feo, Yujin Hoshida, Steven Yea, Sara Toffanin, Alex Ramos, John A Martignetti, Vincenzo Mazzaferro, Jordi Bruix, Samuel Waxman, Myron Schwartz, Matthew Meyerson, Scott L Friedman, Josep M Llovet

Author Affiliations

1: Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA.

Articles citing this

(truncated to the top 100)

miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44

Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85

Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63

Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51

Harnessing transposons for cancer gene discovery. Nat Rev Cancer (2010) 2.44

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem (2011) 1.88

Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71

Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68

AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology (2011) 1.67

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55

Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal (2012) 1.50

UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell (2014) 1.50

Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res (2009) 1.45

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res (2010) 1.43

Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med (2011) 1.38

Sorafenib: where do we go from here? Hepatology (2010) 1.38

Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33

Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer (2012) 1.32

Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ (2011) 1.32

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26

Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev (2010) 1.21

Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling. J Virol (2012) 1.17

Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol (2014) 1.17

MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ (2014) 1.17

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14

Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest (2012) 1.11

Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol (2010) 1.10

Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol (2010) 1.08

Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle (2013) 1.08

JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer (2009) 1.07

Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One (2013) 1.06

Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology (2010) 1.05

Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05

Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol (2015) 1.05

Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma. Int J Biol Sci (2014) 1.05

The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol (2013) 1.04

The mTOR pathway in hepatic malignancies. Hepatology (2013) 1.02

Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol (2013) 1.02

Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis (2010) 1.01

Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol (2010) 1.01

Targeting mTOR pathway: A new concept in cancer therapy. Indian J Med Paediatr Oncol (2010) 0.99

Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer (2012) 0.98

Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia (2009) 0.98

Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol (2014) 0.96

Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol (2013) 0.95

Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget (2012) 0.95

Mechanisms of GOLPH3 associated with the progression of gastric cancer: a preliminary study. PLoS One (2014) 0.95

Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation. Oncogene (2012) 0.95

Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. J Hepatol (2012) 0.95

Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci (2011) 0.94

Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma. Mol Med (2012) 0.94

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol (2010) 0.94

Blocking autophagic flux enhances matrine-induced apoptosis in human hepatoma cells. Int J Mol Sci (2013) 0.94

Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant (2014) 0.94

Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice. Hepatology (2013) 0.94

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer (2010) 0.93

Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS One (2013) 0.93

Hepatocellular carcinoma: Where there is unmet need. Mol Oncol (2015) 0.93

Current and future treatments for hepatocellular carcinoma. World J Gastroenterol (2015) 0.92

Hepatocellular carcinoma: Where are we? World J Exp Med (2016) 0.92

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol (2013) 0.91

Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis. Cancer Med (2013) 0.91

Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST. Sarcoma (2012) 0.90

Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines. PLoS One (2009) 0.90

Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. Mol Cell Proteomics (2014) 0.90

4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice. Hepatology (2014) 0.90

A meta-analysis of array-CGH studies implicates antiviral immunity pathways in the development of hepatocellular carcinoma. PLoS One (2011) 0.89

New agents on the horizon in hepatocellular carcinoma. Ther Adv Med Oncol (2013) 0.88

Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology (2012) 0.88

Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. Am J Cancer Res (2014) 0.87

Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol (2012) 0.87

EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology (2014) 0.87

Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol (2015) 0.87

Akt and mTORC1 have different roles during liver tumorigenesis in mice. Gastroenterology (2013) 0.86

The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma. Hepat Mon (2012) 0.86

Cellular reprogramming and hepatocellular carcinoma development. World J Gastroenterol (2013) 0.86

Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol (2014) 0.86

New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer (2011) 0.85

The camKK2/camKIV relay is an essential regulator of hepatic cancer. Hepatology (2015) 0.84

The inhibitory effect of rapamycin on the oval cell response and development of preneoplastic foci in the rat. Exp Mol Pathol (2012) 0.84

Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol (2011) 0.84

Structural and functional hepatocyte polarity and liver disease. J Hepatol (2015) 0.84

New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. Br J Clin Pharmacol (2016) 0.83

Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83

Identification and comparative analysis of hepatitis C virus-host cell protein interactions. Mol Biosyst (2013) 0.83

Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis (2013) 0.83

Effects of statins on the risk of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 0.82

Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. PLoS One (2010) 0.82

Articles cited by this

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46

Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99

GenePattern 2.0. Nat Genet (2006) 29.07

The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11

Hepatocellular carcinoma. Lancet (2003) 22.54

Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02

Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci U S A (1977) 3.25

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther (2006) 2.63

mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res (2007) 2.44

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem (2007) 2.25

Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene (2001) 2.25

mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14

The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med (2007) 2.12

Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer (2003) 2.09

Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene (2006) 1.88

Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol (2004) 1.58

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol (2007) 1.56

Activation of the c-fos enhancer by the erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites. Oncogene (2000) 1.39

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation (2007) 1.29

PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene (1999) 1.20

Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol (2005) 1.09

Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene (2006) 1.04

Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol (2005) 0.95

Articles by these authors

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35

Hepatocellular carcinoma. Lancet (2003) 22.54

Signatures of mutational processes in human cancer. Nature (2013) 21.63

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83

Hepatocellular carcinoma. Lancet (2012) 18.09

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41

Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28

The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13

The genomic complexity of primary human prostate cancer. Nature (2011) 14.06

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

A landscape of driver mutations in melanoma. Cell (2012) 12.61

High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93

MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86

Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08

LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76

Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61

Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48

Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45

Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89

Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10

Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell (2004) 6.08

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04

Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97

Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95

Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88

Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45

The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27

Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res (2004) 5.23

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07